Supernus Pharmaceuticals Inc (SUPN)
Payables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cost of revenue | US$ in thousands | 401,888 | 0 | 467,442 | 382,420 | 257,436 |
| Payables | US$ in thousands | 4,587 | 1,964 | 10,543 | 9,331 | 6,147 |
| Payables turnover | 87.61 | 0.00 | 44.34 | 40.98 | 41.88 |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $401,888K ÷ $4,587K
= 87.61
Supernus Pharmaceuticals Inc's payables turnover has shown an increasing trend from 2020 to 2022, indicating that the company is managing its accounts payable more efficiently. The ratio increased from 41.88 in December 2020 to 44.34 in December 2022. However, the payables turnover ratio dropped to 0.00 in December 2023, which is highly unusual and could be a cause for further investigation. In December 2024, the payables turnover ratio surged to 87.61, which could suggest the company has significantly improved its management of accounts payable, possibly through renegotiating payment terms or optimizing supplier relationships. Overall, the payables turnover ratio reflects Supernus Pharmaceuticals Inc's ability to pay its suppliers and manage its trade credit effectively.
Peer comparison
Dec 31, 2024